Tivdak® (tisotumab vedotin-tftv) significantly prolonged overall survival in patients with recurrent or metastatic cervical cancer compared with chemotherapy in global phase 3 innovatv 301 trial

Copenhagen, denmark & bothell, wash.--(business wire)--genmab a/s (nasdaq: gmab) and seagen inc. (nasdaq: sgen) announced additional results today from the phase 3 innovatv 301 randomized global trial, which showed treatment with tivdak demonstrated a statistically significant and clinically meaningful 30 percent reduction in the risk of death in recurrent or metastatic cervical cancer patients with disease progression on or after front-line therapy, compared with chemotherapy (hr: 0.70, 95 per.
SGEN Ratings Summary
SGEN Quant Ranking